Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$3.29M, compared with $1.25M a year earlier. Trailing-twelve-month net income was -$7.4M. Over 3 fiscal years it compounded at -20.3% a year.
Context
- Net income amounted to 6.4% of revenue in FY2025, down 10.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$8.23M (+187.2%) for the fiscal year ending Dec 2026, a step up from the -55.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.29M+130.1% QoQ
- Last fiscal yearDec 2025
- -$2.86M-55.8% YoY
- LTMMar 2026
- -$7.4M+124.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (2.86M) USD
- Year-over-year change
- +55.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.86M) | +55.8% |
| FY2024 | 2024-12-31 | (6.48M) | -3.2% |
| FY2023 | 2023-12-31 | (6.28M) | -11.1% |
| FY2022 | 2022-12-31 | (5.65M) | -56.8% |
| FY2021 | 2021-12-31 | (3.6M) | — |
Net Income vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 net income of $7.4M is the 3rd largest of the 4 companies compared; the peer median is $15.91M.
- Its year-over-year change of +124.6% is the highest of 4, against a peer median of +25.1%.
- Net income amounts to 17.6% of revenue for CPIX, versus a peer median of 295.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $91.72M | +58.4% | — | 345.4% | |
| LTM Mar 2026 | $15.91M | -19.9% | +6.3% | — | |
| LTM Mar 2026 | $7.4M | +124.6% | -20.3% | 17.6% | |
| LTM Mar 2026 | $7.29M | +25.1% | -8.9% | 245.1% | |
| Peer median (excluding CPIX) | $15.91M | +25.1% | -1.3% | 295.3% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (3.6M) | (5.65M) | (6.28M) | (6.48M) | (2.86M) |
| Depreciation & Amortization | 4.61M | 5.33M | 5.77M | 6.04M | 5.29M |
| Deferred Income Tax | (192.82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 741.87K | 447.5K | 365.04K | 301.9K | 408.32K |
| Change in Working Capital | 8.18M | 10.97M | 4.63M | 1.29M | 2.16M |
| Accounts Receivables | 5.5M | (6.12M) | 3.4M | (1.94M) | (5.24M) |
| Inventory | 4.82M | 1.38M | (23.14K) | 2.41M | 2.24M |
| Accounts Payables | (757.59K) | 15.07M | 3.72M | (991.36K) | 6.71M |
| Other Working Capital | (1.38M) | 644.92K | (2.47M) | 1.82M | (1.55M) |
| Other Non-Cash Items | (3.39M) | (2.64M) | 1.6M | (1.77M) | (59.95K) |
| Operating Cash Flow | 6.34M | 8.45M | 6.09M | (612.19K) | 4.93M |
| Capital Expenditures | (354.46K) | (2.07M) | (453.05K) | (179.71K) | (97.9K) |
| Acquisitions (Net) | 0 | (13.5M) | 0 | 0 | 0 |
| Purchases of Investments | (200K) | 0 | 0 | 0 | (4.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 52.57K | 1.9M | 347.36K | 237.56K | (47K) |
| Investing Cash Flow | (501.89K) | (13.67M) | (105.7K) | 57.84K | (4.71M) |
| Debt Repayment | 0 | 1.2M | (3.42M) | 2.49M | (10.04M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 5.27M |
| Common Stock Repurchased | (1.39M) | (1.05M) | (740.53K) | (579.05K) | (263.48K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | (2.21M) | (3.27M) | (1.72M) | (1.71M) |
| Financing Cash Flow | (3.55M) | (2.06M) | (7.42M) | 196.9K | (6.75M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.29M | (7.28M) | (1.44M) | (357.44K) | (6.52M) |
| Free Cash Flow | 5.99M | 6.38M | 5.64M | (791.9K) | 4.83M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.